[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-reflux-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-reflux-in-children":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100389996",false,"NCT04358146","Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)","Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial","STELLAR","Inclusion Criteria:\n\n* ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days,\n* exclusive or predominant formula feeding\n* whose parents signed informed consent\n\nExclusion Criteria:\n\n* preterm infants or birthweight \\\u003C2500g\n* Post enteritis lactose intolerance\n* Suspected or diagnosed cow's milk protein allergy requiring an eviction diet\n* Use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). All these medications have to be stopped at least 7 days before inclusion visit (V1)\n* Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject","ALL","2 Weeks","4 Months",{"count":20,"type":21},346,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.",[27],"Gastroesophageal Reflux in Children",[29],"Reflux","RECRUITING","2026-04-30",{"date":33,"type":34},"2026-05-04","ACTUAL",{"date":36,"type":34},"2023-03-17",{"date":38,"type":21},"2026-12-03",{"name":40,"class":41},"United Pharmaceuticals","INDUSTRY",12,""]